CEBPZ and acute myeloid leukemia: These findings indicate that the inconsistent reporting of KIT mutation-related risks in the prognosis of t(8,21) AML also exists in pediatric patients; the systematic review also implied that pediatric CBF-AML should not be treated as a group but rather as t(8,21) and inv(16) AML subgroups.